Yüklüyor......

Clinical Challenges to Current Molecularly Targeted Therapies in Lung Cancer

Lung cancer is difficult to treat with a poor prognosis and a five year survival of 15%. Current molecularly targeted therapies are initially effective in non-small cell lung cancer (NSCLC) patients; however, they are plagued with difficulties including induced resistance and small therapeutically r...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Arch Cancer Res
Asıl Yazarlar: Chhabra, Gagan, Eggert, Ashley, Puri, Neelu
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2015
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4894332/
https://ncbi.nlm.nih.gov/pubmed/27280107
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!